Clinical Trials · NCT06974825
A Study of BGM0504 in Chinese Patients With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Enrollment
- 67
- Start date
- Aug 2023
- Locations
- 1 site, China
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c)